跳至主要内容
临床试验/NCT02866487
NCT02866487已完成不适用

Lung Fluid and Peripheral Blood Neutrophil IL-5 Surface Receptor in Children With Asthma

University of Virginia1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2016年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
72
试验地点
1
主要终点
Percent neutrophils bearing surface markers for IL-5 Receptor

研究概览

简要总结

The pattern of lower airway inflammation in asthma is heterogeneous, but in many patients, the polymorphonuclear neutrophil (PMN) is the predominant granulocyte infiltrating the airspaces. Although it is known to have an important function in innate immune defense, the role of the PMN in asthma has not been well elucidated. In work in progress, the investigators have identified the receptor for IL-5 on the surface of bronchoalveolar lavage (BAL) PMNs in a subset of children with severe, treatment-resistant asthma, a characteristic that is not found in peripheral blood neutrophils. While the function of this IL-5 receptor has yet to be determined, preliminary evidence strongly supports a mechanism linking neutrophilic with type 2 inflammation in the lower airways of children with asthma, a discovery that has exciting potential to modify the treatment of asthma.

The primary objective of this observational cross-sectional study is to test the overall hypothesis that therapeutic intervention directed against the IL-5R on lung PMNs will decrease inflammation and improve clinical outcomes in patients with poorly controlled asthma. The secondary study objective is to demonstrate that IL-5R expression on lung-infiltrating PMNs is functional, will activate known IL-5R-induced signaling pathways, and will lead to enhanced PMN pro-inflammatory activity including increased PMN recruitment, prolonged survival, degranulation, and release of reactive oxygen species.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
— 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Ages 0-17
  • Treatment-resistant, refractory respiratory symptoms
  • Scheduled for a clinical diagnostic bronchoscopy

排除标准

  • Known lower respiratory tract infection within 60 days of scheduled bronchoscopy
  • Systemic disorders involving the heart, respiratory system, CNS, renal, and endocrine systems

结局指标

主要结局

Percent neutrophils bearing surface markers for IL-5 Receptor

时间窗: 6+ months post bronchoscopy

The percentage of neutrophils which bear surface markers for the IL5-R in lung fluid and peripheral blood will be compared in children with different asthma phenotypes

次要结局

  • In vitro analysis of IL-5 Receptor (IL-5 R) function: Signaling via the IL-5 R displayed on neutrophils from the BAL (and if necessary, peripheral blood) following ligand (IL-5) binding(48-72 hours post bronchoscopy)
  • Measurement of neutrophil degranulation and inflammatory mediator production following IL-5 binding to its receptor on neutrophils isolated from the BAL(48-72 hours post bronchoscopy)
  • Production of Reactive Oxygen Species following IL-5 R engagement(48-72 hours post bronchoscopy)
  • Measurement of neutrophil survival in culture upon IL-5 R engagement in vitro(48-72 hours post bronchoscopy)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Willliam Gerald Teague

Ivy Foundation Distinguished Professor of Pediatrics

University of Virginia

研究点 (1)

Loading locations...

相似试验